RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: The Company designs, develops, manufactures, and markets safety syringes (VanishPoint®) and blood collection tube holders. Operations are based in Little Elm, Texas. The Company faces market access challenges due to exclusive marketing practices by competitor Becton Dickinson & Co. (BD) but is expanding international sales and utilizing a manufacturing agreement with a Chinese partner (Double Dove) to reduce unit costs.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total sales decreased slightly by 2.2% compared to Q1 2004. However, unit sales increased by 23.1%, driven primarily by international sales which grew from 3.6% of revenue in 2004 to 23.4% in 2005. International sales typically have a lower average price than domestic sales.
• Profitability: Gross margin improved significantly from 26.0% to 35.6% due to lower unit costs resulting from increased production volumes and manufacturing in China. Loss from operations decreased by 51.0%.
• Expenses: General and administrative expenses declined significantly due to reduced legal costs associated with antitrust and patent infringement litigation. Sales and marketing expenses increased due to sales force expansion and travel costs.
• Cash Flow: Net cash used by operating activities was $1.65 million, compared to $1.97 million in the prior year. Investing activities used $1.04 million, primarily for the completion of a new warehouse building. Financing activities provided $960,142, consisting of proceeds from a construction loan.
• Liquidity: Cash balances remain strong at $54.1 million, representing 71% of total assets. The current ratio improved from 8.3 to 9.0.

Guidance, Outlook, and Risks

• Outlook: Management does not intend to raise equity capital in 2005, relying instead on cash reserves, operations, and debt financing. The Company aims to achieve a break-even quarter by gaining better access to hospital markets and reducing unit costs through the China manufacturing agreement.
• Market Risks: The Company faces significant market access barriers due to the dominance of Becton Dickinson & Co. (BD). Sales are also subject to seasonality (flu season) and were potentially impacted by the 2004 flu vaccine shortage.
• Preferred Stock Arrears: Significant dividend arrearages exist on all series of Class B Convertible Preferred Stock, totaling approximately $10 million as of the filing date. If dividends are in arrears, no dividends may be paid on common stock.
• Capital Expenditures: The Company has material commitments of $1.5 million for 2005, primarily for warehouse completion and capital assets, funded by loans and cash reserves.
• Controls: Management determined that disclosure controls and procedures were effective as of March 31, 2005.

Investor Verification Checklist

• Preferred Stock Arrears: Verify the total accumulated dividend arrearages on Series I through V Preferred Stock, which restrict common stock dividends and redemptions.
• Customer Concentration: Confirm the reliance on two significant customers who comprised 28.5% of revenues for the quarter.
• Debt Covenants: Review the terms of the $2.5 million loan from 1st International Bank regarding the warehouse construction and repayment schedule.
• Manufacturing Mix: Assess the impact of the China manufacturing agreement on future unit costs and inventory valuation.
• Legal Litigation: Monitor the status of the antitrust lawsuit against Becton Dickinson & Co. and its effect on market access and legal expense volatility.